167 related articles for article (PubMed ID: 12515038)
1. [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia].
Drsata J
Cas Lek Cesk; 2002 Oct; 141(20):630-5. PubMed ID: 12515038
[TBL] [Abstract][Full Text] [Related]
2. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
3. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH).
Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Banchini A; Ablondi F; Valenti G
J Endocrinol Invest; 1999; 22(10 Suppl):70-1. PubMed ID: 10727053
[No Abstract] [Full Text] [Related]
4. [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].
Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE; Kornienko VI; Kuz'min IV
Urol Nefrol (Mosk); 1998; (3):5-8. PubMed ID: 9644979
[TBL] [Abstract][Full Text] [Related]
5. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Brodie AM; Son C; King DA; Meyer KM; Inkster SE
Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464
[TBL] [Abstract][Full Text] [Related]
6. [Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments].
Laszczyńska M; Chorzepa-Nowicka K; Wylot M; Piasecka M; Gaczarzewicz D
Pol Merkur Lekarski; 2008 Dec; 25(150):528-30. PubMed ID: 19205388
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].
Stepanov VN; Teodorovich OV; Seregin AV; Kadyrov ZA
Urol Nefrol (Mosk); 1995; (5):28-30. PubMed ID: 8571480
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy.
Bredin HC
Ir Med J; 1996; 89(3):86, 88. PubMed ID: 8707527
[No Abstract] [Full Text] [Related]
9. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
10. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia.
Weisser H; Tunn S; Behnke B; Krieg M
Prostate; 1996 May; 28(5):300-6. PubMed ID: 8610056
[TBL] [Abstract][Full Text] [Related]
11. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Van Cangh PJ
Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
14. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
Sun ZY; Tu ZH
Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
[TBL] [Abstract][Full Text] [Related]
15. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
16. [Benign prostatic hyperplasia--its treatment with Proscar].
Panchev P; Neĭkov K; Simeonov P
Khirurgiia (Sofiia); 1996; 49(1):15-8. PubMed ID: 8975081
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH).
Rennie PS; Bruchovsky N; McLoughlin MG; Batzold FH; Dunstan-Adams EE
J Steroid Biochem; 1983 Jul; 19(1A):169-73. PubMed ID: 6193340
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
19. [Activity of 5 alpha-reductase in human hyperplastic prostates].
Lin Y
Zhonghua Yi Xue Za Zhi; 1991 May; 71(5):263-5, 20. PubMed ID: 1713809
[TBL] [Abstract][Full Text] [Related]
20. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
